Abstract: Parkinson's disease (PD) is characterized by a progressive degeneration of dopaminergic neurons in the substantia nigra. The neuronal degeneration may result from the convergence of a number of different pathogenic factors, including apoptosis, excitotoxicity and oxidative stress. Many studies emphasize the importance of omega-3 polyunsaturated fatty acids (x-3 PUFAs) in vital processes such as maintenance of the properties of cell membranes and the participation in signal transduction and biodynamic activity of neuronal membranes. In this study, the protective effect of x-3 PUFA administration on the 6-hydroxydopamine (6-OHDA) model of PD in rats was investigated. x-3 PUFA (1.5 and 3.0 g/kg) was orally administered by gavage during 28 consecutive days to male Wistar rats. On the 4th day, hemiparkinsonism was induced through intrastriatal injection of 6-OHDA. On the 25th day, the animals were submitted to behavioural analysis. On the 28th day, after euthanasia, the brain areas were collected for neurochemical evaluation. x-3 PUFAs (1.5 and 3.0 g/kg) restored monoamine and amino acid levels on the striatum from hemiparkinsonian rats, followed by reduction in the number of apomorphine-induced rotations and promotion of a partial locomotor recovery. In addition, x-3 PUFAs (1.5 and 3.0 g/kg) decreased the lipid peroxidation levels and nitrite levels in the brain areas from hemiparkinsonian rats. Thus, this study suggests that supplementation with x-3 PUFAs prevents behavioural and neurochemical disturbances induced by 6-OHDA, presenting a potential neuroprotective action.
Parkinson's disease (PD) is an age-related neurodegenerative disorder that is characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta, markedly reducing dopamine (DA) levels on the striatum. It is considered the second most common neurodegenerative disorder, following Alzheimer's disease and an important cause of chronic disability in the among older population [1, 2] . Clinically, it presents mainly motor symptoms such as muscle rigidity, resting tremor, bradykinesia, postural instability and autonomic abnormalities, which appear when striatal levels of DA are reduced by approximately 80% or more [3] . Although PD aetiology and the nature of its progression are still not completely understood, evidence suggests that the nigral dopaminergic degeneration results from the convergence of different mechanisms, including mitochondrial dysfunction, oxidative stress, apoptosis, excitoxicity, altered protein handling and inflammation [1, 4, 5] . Currently, the focus of PD treatment is the replacement of brain DA content with DA agonists, including the dopaminergic precursor 3,4-dihydroxyphenylalanine (L-DOPA) which is considered to be the most effective drug controlling PD symptoms [6] . Actually, all of the current drugs are unable to affect the course of this disease. Thereby, there is an urgent need for disease-modifying drugs, focusing on novel therapies emphasizing neuroprotective activities [1, [7] [8] [9] .
Polyunsaturated fatty acids (PUFAs) are required for the normal development of the central nervous system, and its deficiency can harm cerebral functions and alter the brain development [10, 11] . PUFAs from the omega-3 family (x-3 PUFAs) are in fatty fish, fish oil and certain plants and are mainly represented by eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [12, 13] . Evidence has shown the involvement of x-3 PUFAs in many processes, such as maintenance of lipid bilayer properties in cell membranes [14, 15] , anti-apoptotic and anti-inflammatory action [10, 16, 17] , participation in signal transduction and in the biodynamic activity of neuronal membranes [12] , regulation of ion channels and receptors [18, 19] and gene transcription [20] . Other works suggest that an adequate dietary intake of x-3 PUFAs can prevent cognitive decline and attenuate the brain physiological disturbances that are associated with ageing, including neurodegenerative disorders such as Alzheimer's disease and PD [11, [21] [22] [23] [24] [25] [26] . Considering the potential modulatory effects of x-3 PUFA supplementation on PD development, the present study investigated the potential neuroprotective action of x-3 PUFAs in a hemiparkinsonian model induced by 6-hydroxydopamine (6-OHDA) in rats.
Materials and Methods
Drugs and reagents.
6-Hydroxydopamine, L-ascorbic acid, apomorphine, sodium o-phthaldialdehyde reagent solution, octane Author for correspondence: Lissiana Magna Vasconcelos Aguiar, Faculty of Medicine, Av. Comandante Mauroc elio Rocha Pontes, 100, 62042-280, Federal University of Cear a, Sobral, Cear a, Brazil (e-mail lissiana.aguiar@ufc.br). sulphonic acid, acetonitrile, tetrahydrofuran, standard monoamines and amino acids were purchased from Sigma (St. Louis, MO, USA). x-3 PUFAs, EPA and DHA were purchased from Ache (Ach e, Guarulhos, Brazil) (Proepaâ -Guarulhos, Brazil). All other drugs were of analytical grade.
Animals. Male Wistar rats (weighing 250-300 g, n = 8 animals per group), from the Animal Care Unit of the Federal University of Cear a, Fortaleza, Brazil, were used for behavioural and neurochemical tests. The animals were housed in standard environmental conditions (22 AE 1°C, humidity 60 AE 5%, 12-hr light:dark cycle) with free access to water and food (rat chow, Nuvital Nuvilab CR1-Nuvital Nutrientes S/A, Brazil). All experiments were approved by the Animal Experimentation Ethics Committee from the Federal University of Cear a and were performed in accordance with the NIH Guide for Care and Use of Laboratory Animals. All efforts were made to minimize the number of animals used and their suffering.
Experimental protocol. Figure 1 shows the experimental protocol used. Initially, animals were divided into four groups (n = 8 animals per group). On the first day, two groups received daily x-3 PUFAs (1.5 and 3.0 g/kg, respectively) diluted in soya bean oil (containing 180 mg of EPA and 120 mg of DHA) by gavage during 28 consecutive days. The other two groups were used as controls (the sham-operated and 6-OHDA). On the 4th day, after 1 hr of the treatment with x-3 PUFAs, all animals were anaesthetized with ketamine (100 mg/kg, i.p.) and xylazine (5 mg/kg, i.p.) and submitted to stereotaxic surgery with unilateral injection of 2 lL of 6-OHDA (3 mg/mL, with 0.2 mg/mL L-ascorbic acid, per site) into the right striatum (ipsilateral side). The unilateral, intrastriatal 6-OHDA injection was performed through a 6-lL Hamilton â syringe using a Behavioural analysis. The behavioural analyses were performed 3 weeks after the animals received the 6-OHDA treatment (25th day). The animals were killed 3 days after testing for rotational behaviour (28th day), in accordance with Cansev et al. [28] .
Open-field test. The open-field (OF) area was made of acrylic (transparent walls and black floor, 60 cm 9 60 cm 9 60 cm) divided into twelve quadrants. The OF was used to evaluate the locomotor activity of the rats. Each rat was gently placed in the centre of the open field and was allowed to freely explore the area for 5 min. Three motor parameters were obtained throughout this test: locomotion frequency (number of crossings from one quadrant to the other), rearing frequency (number of times the animals stood on their hind paws) and immobility time (number of seconds of lack of movement during testing). Before introducing each animal, the arena was cleaned with 5% water-ethanol solution to eliminate the possible bias due to the odour that could be left by previous animals [29] .
Rotational behaviour. The behaviour was assessed by monitoring body rotations induced by apomorphine (3 mg/kg, intraperitoneally). The number of net rotations (the number of 360°contralateral turns) was recorded for 60 min. [30] .
Neurochemical analysis. On the 28th day, all animals were killed, and hippocampus (HC), striatum (S, ipsilateral side) and prefrontal cortex (PFC) were collected and stored at À80°C until use.
Evaluation of lipid peroxidation (thiobarbituric acid-reactive substances assay). The HC, S and PFC from all groups were dissected to prepare 10% homogenates in 1.15% KCl (w/v). The formation of lipid peroxides during lipid peroxidation was followed by measuring the thiobarbituric acid-reactive substances (TBARS), as previously described by Draper and Hadley [31] . Briefly, samples were mixed with 1 mL of 10% trichloroacetic acid and 1 mL of 0.6% thiobarbituric acid. The reaction medium was heated in a boiling water bath for 15 min., and n-butanol (2:1 v/v) was added to the media. After centrifugation (800 9 g, 5 min.), TBARS contents were determined at 535 nm. The data were expressed as lg malondialdehyde (MDA)/g of tissue.
Nitrite level determination. Tissue samples from HC, S or PFC were used to prepare 10% homogenates in 1.15% KCl (w/v). After centrifugation (800 9 g, 10 min.), supernatants were collected and the nitric oxide production was determined by the Griess reaction [32] . Briefly, 100 lL of the supernatant was incubated with 100 lL of the Griess reagent [1% sulphanilamide in 1% H 3 PO 4 /0.1% N-(1-naphthyl)-ethylene diamine dihydrochloride/1% H 3 PO 4 /distilled water (1:1:1:1)] at room temperature for 10 min. The absorbance was measured at 550 nm with a microplate reader. Nitrite concentration (lM) was determined from a standard NaNO 2 curve. The data were expressed as lM nitrite (NaNO 2 )/g of tissue.
Monoamine level determination. For the measurement of monoamine levels and their metabolites, noradrenaline (NE), DA, 3,4 dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA), striatum (ipsilateral side) from all groups was dissected to prepare a 10% homogenates. The homogenates were sonicated in 0.1 M HClO 4 for 30 sec., followed by centrifugation at 4°C for 15 min. at 12,000 9 g and filtration of the supernatant (0.2 lm; Merck Millipore, Darmstadt, German). A 20-lL sample was then injected into a high-performance liquid chromatography (HPLC) column. The mobile phase was 0.163 M citric acid, pH 3.0, containing 0.02 mM EDTA, with 0.69 mM sodium octane sulphonic acid (SOS), as ion-pairing reagent, 4% v/v acetonitrile and 1.7% v/v tetrahydrofuran. NE, DA, 5-HT and their metabolites were electrochemically detected, using an amperometric detector (Shimadzu, Kyoto, Japan), by oxidation on a glassy carbon electrode at 0.85 V relative to the Ag-AgCl reference electrode [33] . The concentrations of monoamines were determined by comparison with standards injected into the HPLC column on the day of experiment and the results expressed as ng/mg of tissue.
Fig. 1. Experimental design.
Measurement of extracellular glutamate and gamma-aminobutyric acid. Glutamate and gamma-aminobutyric acid (GABA) were determined on a HPLC system with pre-column derivatization with ophthaldialdehyde/2-mercaptoethanol/borate reagent (pH 10.4) and fluorimetric detection [34] . Briefly, striatum (ipsilateral side) from all groups was dissected to prepare 10% homogenates (in 0.1 M perchloric acid). Then, the homogenates were derivatized with the same volume of the o-phthaldialdehyde reagent solution and after 60 sec. injected into an HPLC column (4-mm, C18 reverse-phase from Shimadzu). The mobile phase A (pH 6.95) was composed of sodium acetate (0.1 M), methanol (6%) and tetrahydrofuran (1.5%), and the mobile phase B was 100% methanol with a flow of 1.0 mL/ min. in a gradient. The fluorimetric detector (Model RF 535; Shimadzu) had the excitation and emission wavelengths set at 370 and 450 nm, respectively. The concentrations of amino acids were determined by comparison with standards injected into the HPLC column on the day of experiment and the results expressed as lM/g of tissue.
Statistical analysis. All the data were presented as means AE S.E.M. One-way ANOVA was used, followed by Tukey's post hoc test, and the results were considered significant at p < 0.05.
Results
Effects of x-3 PUFA supplementation in the behaviour of hemiparkinsonian rats. fig. 3 ).
Neurochemical analysis of brain areas from hemiparkinsonian rats supplemented with x-3 PUFAs.
Lipid peroxidation. However, hemiparkinsonian animals supplemented with x-3 PUFAs (1.5 and 3.0 g/kg) showed a significant reduction (p < 0.001) on the nitrite levels in all areas tested (S: 11.2 AE 0.9 and 7.5 AE 1.0; HC: 8.6 AE 0.7 and 9.0 AE 0.7; and PFC: 8.3 AE 0.6 and 8.7 AE 0.5 lM of nitrite/g of tissue, respectively) in comparison with the 6-OHDAlesioned group. fig. 7A,B) . The alterations were lower in hemiparkinsonian animals supplemented with x-3 PUFAs (1.5 and 3.0 g/kg) (GLU: 4.8 AE 0.45 and 0.95 AE 0.14; GABA, 13.44 AE 1.19 and 5.6 AE 0.44 lM/g of tissue, respectively), in relation to the 6-OHDA-lesioned group.
Discussion
Beneficial effects of x-3 PUFAs have been reported in epidemiological, preclinical and clinical studies, suggesting that this PUFA family may constitute a therapeutic strategy for several disorders affecting the CNS, including PD [35] [36] [37] [38] [39] [40] [41] [42] . Although specific mechanisms of action of x-3 PUFAs remain unknown, evidence points out that anti-inflammatory [43] [44] [45] [46] , antioxidant [46] [47] [48] and anti-apoptotic actions may be involved [49, 50] . The present study showed the effects of chronic supplementation of x-3 PUFAs in rats submitted to a hemiparkinsonian model induced by 6-OHDA.
6-OHDA neurotoxin induces nigrostriatal damage and impairs dopaminergic neurotransmission. The extent of the nigrostriatal lesion is routinely evaluated according to physical disabilities using rotational behaviour of the animal, after the administration of dopaminergic drugs and spontaneous motor tests like the open-field test [51] . In this present work, our results showed that 6-OHDA produced an increase in the number of contralateral rotations induced by apomorphine. This effect was probably caused by sensitization and up-regulation of dopaminergic receptors on contralateral side due to the loss of dopaminergic terminals in the ipsilateral side [52] . Furthermore, the chronic administration with x-3 PUFAs (1.5 and 3.0 g/kg) partially prevented the impairment induced by 6-OHDA, promoting a significant reduction in rotational behaviour as well as increasing the locomotor activity. This recovery is probably due to the beneficial effects of x-3 PUFAs attenuating neuronal degeneration of dopaminergic cells and decreasing the process of sensitization of dopaminergic receptors [53] . Bousquet et al. [35] reported that chronic x-3 PUFA dietary intake was able to protect neurons from neurotoxicity using an animal model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. The study demonstrated that mice supplemented during 10 months with a high dose of x-3 PUFAs (5.3 g/kg) exhibited a profile of fatty acid modified in the brain while some nigral and striatal dopaminergic components were protected from MPTP-induced neurotoxicity. Similarly, Tanriover et al. [54] , using the PD model induced by MPTP, demonstrated that the oral intake of DHA presented neuroprotective effects by reduction of damage on dopaminergic neurons of substantia nigra and decreasing motor deficits. Furthermore, the authors report that DHA increased expression of glial cell line-derived neurotrophic factor and neurturin. In corroboration of this, Shin and Dixon [55] report that x-3 PUFA diet consisting of both DHA and EPA promote the increase in the transcription of brain-derived neurotrophic factor (BDNF) messenger RNA on the striatum and elevated BDNF protein levels in the motor cortex. As these neurotrophic factors induce neural growth and development, their induction may be a possible mechanism of neuroprotection induced by x-3 PUFA supplementation.
The mechanisms involved in neurodegeneration that occurs in the PD is not completely understood; however, it is known that some events are involved in the development of this pathology, including the imbalance of oxidative stress. Evidence suggests that increased lipid peroxidation and antioxidant system failure are important players in this process [56, 57] . Therefore, we evaluated the changes in the oxidative stress caused by 6-OHDA on the HC, striatum and PFC from hemiparkinsonian rats supplemented with x-3 PUFAs by lipid peroxidation and nitrite level measurements. As expected, we showed that 6-OHDA increased lipid peroxidation in the striatum. This oxidative damage affected also the PFC and the HC as well, demonstrating that the progressive injury produced by 6-OHDA is not restricted to neurons of the nigrostriatal pathway. These results corroborated with other studies relating the 6-OHDA deleterious effects on many brain regions such as PFC and HC [58] [59] [60] . The antioxidant effects of the x-3 PUFA supplementation as demonstrated by us were also observed in a study conducted by Sarsılmaz et al. [61] , showing that x-3 PUFAs reduced the levels of lipid peroxidation on the striatum from rats. In accordance with author, possibly x-3 PUFAs induce the inhibition of phospholipase A 2 enzyme which may lead to stabilization of membrane structure and diminishing of reactive oxygen species (ROS) production and lipid peroxidation. Others studies demonstrated that the beneficial effect of fish oil supplementation seems to be, at least partly, due to the antioxidant and anti-inflammatory actions of x-3 PUFAs [24, 62] .
In vitro and in vivo studies of neurodegenerative diseases have demonstrated that peroxynitrite formation may be the key mediator of nitric oxide toxicity [63, 66] . Our results showed that x-3 PUFAs were able to reduce concentrations of nitrite on the striatum, HC and PFC of 6-OHDA-lesioned rats. In fact, evidence suggesting protective effects of x-3 PUFAs related to reduction in levels of nitrite occurs in a large variety of recent studies. Karapehlivan et al. [67] showed protective effect of omega-3 fatty acid against mercury chloride intoxication in mice, suggesting that this effect occurred by improving antioxidant status and acute phase response in mice. In this present study, we showed that supplementation with x-3 PUFAs was able to reduce injuries associated with intracerebral injection of 6-OHDA in rats. Reduction in lipid peroxidation and nitrite levels shown in our work could, at least in part, explain that the protective effect of x-3 PUFAs can act through an antioxidant activity.
3,4 Dihydroxyphenylacetic acid and HVA are two important intermediates in the metabolic course of the DA, and they can directly reflect the change of DA in CNS. Furthermore, studies suggested that in both animals submitted to PD models and patients with PD, there was a reduction in DA content and its metabolites in the process of PD, especially DOPAC and HVA [53, [68] [69] [70] [71] . Thereby, our results agree with those of Han et al. [71] , in the way that 6-OHDA decreases the concentration of DA, DOPAC and HVA in the rat striatum. On the other hand, the supplementation with x-3 PUFAs clearly demonstrated the ability to attenuate 6-OHDAinduced depletion of striatal DA, DOPAC and HVA as well as other neurotransmitters like NE, 5-HT and its metabolite 5-HIAA. These results indicated that x-3 PUFAs may protect dopaminergic neurons in the striatum from cell death caused by 6-OHDA.
It is known that the balance between the neurotransmitters DA, glutamate and GABA is critical in maintaining normal function of the basal ganglia. Moreover, an imbalance between GABAergic neurons activated by D1 receptors and glutamate neurons inhibited by D2 receptors probably plays a major role in the pathogenesis of movement disorder [72] [73] [74] [75] . The increase in glutamate activity in the subthalamic nucleus is responsible for overactivity of basal ganglia output structures, which are also directly under the control of the striatum [76, 77] . Therefore, a proposed therapeutic strategy for PD control is to reduce the activity of glutamate in the striatum [78, 79] . In the present study, we observed that glutamate high concentrations induced by 6-OHDA in rat striatum were attenuated by supplementation with x-3 PUFAs. This reduction in the glutamate levels of hemiparkinsonian rats with x-3 PUFAs and consequent partial restoration of balance between DA and glutamate neurotransmitters probably contributed to the motor recovery observed in the behavioural tests. These results are consistent with previous reports indicating a modulation of glutamatergic neurotransmission exerted by PUFAs [24, 49, 80] .
It has been shown that experimental parkinsonism not only alters the excitatory transmission but also modifies striatal GABAergic inhibitory tone. Neurochemical studies using in vivo animal models have shown that DA denervation induced by 6-OHDA increases basal levels of GABA and/or stimulates GABA release in the striatum [81] [82] [83] . In the present work, we showed that x-3 PUFA supplementation in hemiparkinsonian rats promoted a reduction in the concentrations of GABA to striatal baseline levels. These findings suggest that x-3 PUFA protects the GABAergic pathway against alterations induced by 6-OHDA and possibly restores the balance between the neurotransmitters in the lesioned striatum. Thus, we demonstrated that x-3 PUFAs promoted an improvement of the animal behavioural disturbances and these effects may be related to the x-3 PUFA antioxidant activity, which resulted in the protection of dopaminergic neurons against the harmful action of free radicals produced by 6-OHDA. Furthermore, the supplementation with x-3 PUFAs contributed to recovery of DA levels and the normalization of GABAergic, serotonergic and glutamate pathway.
In conclusion, x-3 PUFAs presented neuroprotective activity against locomotor and behavioural disturbances induced by 6-OHDA, acting in the maintenance of monoaminergic, glutamatergic and GABAergic systems and protected the brain areas against oxidative stress. Therefore, our data suggest that x-3 PUFAs show potential application as a dietary supplement for the treatment of PD.
